I wouldn't be to concerned about the lovenox unifill analyst talk, cripdo's on the money with (it could also just be the analyst speculating). Things are too far down the track with the relationship & there's plenty of media talk/speculation about both companys.
Sanofi is probably making a Lovenox derivative that enhances any shortfalls in the original formula and anchored with our "game changer", lol, will knock the socks off any generic, and stop them in their tracks come future patent-cliff plays.
Bring on the RTFS sales contracts in 2012.
UNS Price at posting:
59.5¢ Sentiment: LT Buy Disclosure: Held
